CYTR : Summary for CytRx Corporation - Yahoo Finance

U.S. Markets close in 5 hrs 14 mins

CytRx Corporation (CYTR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.44+0.02 (+3.94%)
At close: 4:00PM EST
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close0.42
Bid0.05 x 2000
Ask0.68 x 10000
Day's Range0.41 - 0.44
52 Week Range0.36 - 3.66
Avg. Volume1,479,481
Market Cap47.24M
PE Ratio (TTM)-0.49
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire14 days ago

    CytRx to Present at the 19th Annual BIO CEO & Investor Conference

    LOS ANGELES, Feb. 6, 2017 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven A. Kriegsman and David Haen, Vice President of Business Development and Investor Relations, will present a corporate update at the 19th Annual BIO CEO & Investor Conference on Monday, February 13th at 4:00 p.m. Eastern Time at the Waldorf Astoria Hotel in New York City. Based on positive, statistically significant results from CytRx's pivotal Phase 3 trial evaluating aldoxorubicin compared to investigator's choice in patients with previously treated relapsed or refractory sarcomas, CytRx is scheduled to meet with the FDA this quarter to discuss the regulatory path for a New Drug Application (NDA). CytRx Corporation is a biopharmaceutical research and development company specializing in oncology.

  • PR Newswire2 months ago

    CytRx Granted Type B Pre-NDA Meeting with U.S. FDA for Registration Pathway with Aldoxorubicin as a Treatment for Patients with Relapsed Soft Tissue Sarcomas

    LOS ANGELES, Jan. 4, 2017 /PRNewswire/ -- CytRx Corporation (CYTR), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing new therapeutics to treat patients with cancer, today announced that, in response to a request from the company, the U.S. Food and Drug Administration (FDA) has agreed to a Type B pre-NDA meeting at which the company will seek input on its planned New Drug Application (NDA) for aldoxorubicin as a new second-line treatment for patients with soft tissue sarcomas (STS).  Assuming a positive outcome from this pre-NDA meeting, CytRx expects to submit an NDA for aldoxorubicin to the FDA in the last quarter of 2017, and, subject to FDA approval, bring aldoxorubicin to market next year.

  • Zacks2 months ago

    Is the Options Market Predicting a Spike in CytRx Corp (CYTR) Stock?

    Options traders are pricing in a big move for CytRx Corp (CYTR) shares as it has huge implied volatility